Biotech Growth Trust (BIOG); report NAV per share fell 5.6% in 1H 2020

Published on 13-11-2019 08:51:22
Author Sparks Team

For the six months ended 30 September 2019, Biotech Growth Trust’s NAV per share fell 5.6% to 743.1p, which compares favorably with a fall of 5.9% in the benchmark NASDAQ Biotechnology Index. Discount of the company’s share price to NAV narrowed to 6.1% as at 30 September 2019 against 6.7% at the beginning of the period.

The major contributors to the performance during the period were Deciphera Pharmaceuticals, Hansoh Pharmaceutical, Apellis, Karyopharm Therapeutics and Acadia Pharmaceuticals. The major negative contributors to the performance during the period were Sarepta Therapeutics, Regeneron Pharmaceuticals, Alexion, Adverum Biotechnologies and Mirati Therapeutics.

Share this with friends and colleagues